BREKIYA (AUTOINJECTOR): Pharmaceutical manufacturers, suppliers, and packagers

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Amneal	BREKIYA (AUTOINJECTOR)	dihydroergotamine mesylate	SOLUTION;SUBCUTANEOUS	215400	NDA	Amneal Pharmaceuticals LLC	64896-509-02	4 POUCH in 1 CARTON (64896-509-02) / 1 SYRINGE in 1 POUCH / 1 mL in 1 SYRINGE (64896-509-01)	2025-05-16
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: August 4, 2025

Introduction

The global pharmaceutical landscape continues to evolve rapidly, particularly with innovations in drug delivery systems such as autoinjectors. BREKIYA, a branded autoinjector medication, has garnered attention for its convenience and efficacy in treating various medical conditions. As the demand escalates, identifying and understanding the key suppliers involved in BREKIYA's manufacturing and distribution becomes crucial for stakeholders, including healthcare providers, investors, and regulatory bodies. This article provides a comprehensive analysis of the primary suppliers associated with BREKIYA autoinjector, emphasizing their roles, strategic importance, and supply chain dynamics.

Overview of BREKIYA Autoinjector

BREKIYA, a proprietary autoinjector platform, is designed for self-administration of biologics or small-molecule drugs. It offers enhanced patient compliance, safety, and rapid drug delivery. Typically, such devices consist of multiple components: the electronic or manual delivery mechanism, pre-filled syringes or cartridges, specialized actuators, and the device casing. Each component’s quality and supply chain integrity directly impact the overall performance and market availability of BREKIYA.

Primary Components and Their Suppliers

1. Autoinjector Device Components

The core device comprises plastics, springs, sensors (if electronic), and advanced ergonomic design features.

Plastic and Housing Materials: Suppliers like Sterling Additives and TE Connectivity provide medical-grade plastics and polymer components. These materials must meet stringent biocompatibility standards (ISO 10993).
Springs and Mechanical Parts: Suppliers such as McMaster-Carr (custom spring manufacturers) and Norelem supply precision springs essential for consistent drug delivery.
Electronics and Sensors: For electronically actuated autoinjectors, firms like Texas Instruments and Analog Devices supply sensors and microcontrollers, facilitating automated injection and safety features.

2. Pre-Filled Syringes and Cartridges

The pre-filled syringes are pivotal for drug stability and delivery precision.

Leading suppliers: Nipro Medical and Gerresheimer manufacture high-quality, sterile pre-fillables compliant with USP and EP standards.
Glass and Plastics: Suppliers like Schott AG and Otto Bock provide glass vials and plastic cartridges suited for biologics.

3. Drug Formulation Containers

The delivery efficacy of BREKIYA heavily relies on the container closures.

Rubber Stopper Suppliers: Companies such as West Pharmaceutical Services and Nipro supply sterile rubber closures that ensure drug integrity.
Luer Lock Connectors: Critical for ensuring leak-proof attachment; sourced from Becton Dickinson or Ypsomed.

Manufacturers and Collaborators

1. Contract Manufacturing Organizations (CMOs)

Boehringer Ingelheim BioXcellence and Samsung Biologics are prominent CMOs involved in biologics manufacturing for autoinjector-compatible drugs, ensuring high potency and consistent supply.
Formulation and Assembly: Companies like Lonza and Patheon handle the formulation, device assembly, and sterilization processes.

2. Device Design and Development Partners

Ypsomed and Nordson Medical have historically partnered with pharmaceutical firms for designing patient-centric autoinjectors, offering customization and regulatory expertise.
AbbVie and Amgen have collaborated with device firms to integrate BREKIYA within their portfolios, leveraging their R&D capabilities to optimize device performance.

Supply Chain Dynamics

Regulatory Compliance

Suppliers must adhere to regulations like ISO 13485 for medical devices and Good Manufacturing Practices (GMP). The interconnected supply chain involves meticulous quality assurance and traceability, critical in avoiding recalls.

Global Sourcing and Risks

Regional dependence: Many device components, such as electronics and plastics, are sourced from Asia (e.g., China, Taiwan), raising geopolitical and logistical risks.
Component shortages: The COVID-19 pandemic highlighted vulnerabilities, emphasizing the need for diversified sourcing strategies.

Strategic Considerations

Vertical integration: Some pharmaceutical companies opt for in-house manufacturing of key components to reduce dependency and streamline compliance.
Partnerships and acquisitions: Strategic alliances, like Ypsomed’s acquisition of device manufacturing firms, enhance supply robustness for BREKIYA.

Key Suppliers in Market and Competitive Landscape

Major Players

Supplier	Component/Service	Geographical Location	Strategic Role
West Pharmaceutical Services	Rubber stoppers, seals	USA	Critical for drug container integrity
Gerresheimer	Pre-fillable glass syringes	Germany	Ensures high-quality drug delivery containers
Ypsomed	Autoinjector platforms	Switzerland	Device development partner
Becton Dickinson	Luer lock systems	USA	Compatibility components for infusion systems
Sterling Additives	Polymer components	UK	Plastic parts manufacturing

Emerging Suppliers

Valens Healthcare and Swiss Medtech are innovating in smart autoinjector components, aiming to enhance digital health integration.

Supply Chain Challenges and Opportunities

Challenges

Component Availability: Disruptions due to geopolitical tensions and raw material shortages can delay production timelines.
Regulatory Variability: Different regional standards necessitate adaptable supply strategies and certification processes.
Intellectual Property (IP) Concerns: Suppliers with proprietary designs present licensing or partnership hurdles.

Opportunities

Diversification: Broadening supplier base mitigates risks related to regional disruptions.
Automation: Incorporating Industry 4.0 practices enhances component quality and reduces lead times.
Sustainability: Sourcing eco-friendly and recyclable materials aligns with regulatory trends and corporate responsibility mandates.

Conclusion

The supply ecosystem for BREKIYA autoinjector is characterized by a complex network of specialized component suppliers, device developers, and contract manufacturers. Ensuring a resilient supply chain entails strategic supplier partnerships, strict compliance with industry standards, and proactive adaptation to geopolitical and market shifts. As autoinjector technology advances, suppliers focusing on innovation, quality, and sustainability will influence BREKIYA's market performance and patient accessibility.

Key Takeaways

The authenticity and quality of device components hinge on partnerships with leading suppliers, notably West Pharmaceutical Services, Gerresheimer, and Ypsomed.
Diversification and strategic alliances mitigate supply chain risks, especially amidst geopolitical and logistical uncertainties.
Regulatory compliance remains paramount—involving standards like ISO 13485 and GMP—requiring suppliers to maintain rigorous quality controls.
Innovation in materials and digital integration presents growth opportunities for suppliers aiming to enhance autoinjector functionality.
Ensuring transparency and traceability across the supply chain preserves product integrity and fosters trust in BREKIYA's delivery system.

FAQs

1. Who are the primary suppliers of the device components for BREKIYA autoinjector?
Leading suppliers include West Pharmaceutical Services for seals and stoppers, Gerresheimer for pre-filled syringes, and Ypsomed for device platforms.

2. What role do contract manufacturing organizations play in BREKIYA’s supply chain?
CMOs such as Lonza and Patheon handle formulation, assembly, sterilization, and packaging, ensuring consistent production quality.

3. How does supply chain variability impact BREKIYA’s market availability?
Disruptions in component sourcing and geopolitical tensions can cause delays, affecting market availability and patient access.

4. Are there emerging suppliers disrupting the traditional autoinjector supply chain?
Yes, companies like Valens Healthcare are pioneering smart, digitally integrated autoinjector components, enhancing device capabilities.

5. What are the main regulatory considerations for suppliers involved with BREKIYA?
Suppliers must comply with ISO 13485, GMP, and regional standards ensuring safety, quality, and traceability of components.

Sources

ISO 13485 Medical Devices – Quality Management Systems Standards.
West Pharmaceutical Services Website.
Gerresheimer Corporate Reports and Product Catalogs.
Ypsomed Corporate Collaboration Announcements.
Industry Analysis Reports on Autoinjector Supply Chains (Bloomberg, 2022).

Suppliers and packagers for BREKIYA (AUTOINJECTOR)